Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 435 results found. Search for [ Serum Institute of India vaccine trials ]

Results 100 to 120 of 435
BusinessToday.In
January 3, 2021
COVID-19 vaccines in India: Oxford-AstraZeneca's coronavirus vaccine Covishield and Bharat Biotech's COVID vaccine Covaxin will be India's first vaccines


BusinessToday.In
January 3, 2021
Coronavirus vaccine trials: Bharat Biotech said that it is steadily moving towards its goal of 26,000 volunteers. Phase 3 of human clinical trials for Covaxin began in mid-November


BusinessToday.In
January 2, 2021
The SEC has recommended Covaxin for emergency use authorisation; the recommendation, along with rollout modalities, will now be taken up by the DCGI for a final decision on the matter


BusinessToday.In
January 2, 2021
Experts will review the indigenously developed vaccine a day after the Subject Expert Committee (SEC) had recommended Serum-Oxford's Covishield COVID-19 vaccine to the Drugs Controller General of India (DCGI) for emergency use authorisation


BusinessToday.In
January 2, 2021
Covishield DCGI approval: Pune-based Serum Institute will have to provide safety, efficacy and immunogenicity data from the ongoing clinical trials in India and globally


BusinessToday.In
January 1, 2021
Covishield has become the first coronavirus vaccine to receive a regulatory nod in India. Now, Drug Controller General of India (DCGI) will take a final call on rolling out the inoculation


BusinessToday.In
New Delhi, December 31, 2020
Covishield, the COVID-19 vaccine developed by Pune-based Serum Institute of India and AstraZeneca-Oxford University is on verge of getting emergency approval in India for distribution among at-risk people. The institute's CEO Adar Poonawalla took India Today TV's Rahul Kanwal around the Covishield factory, where millions of vaccine vials are produced, packaged and stored, to show and explain the process behind the production of the Covid vaccine. Watch the video for more.Also Read: Moderna's COVID-19 jab reveals 94.1% efficacy in trials


BusinessToday.In
December 31, 2020
The ministry has also said that programme managers and implementers must plan to prevent and minimise preventable Adverse Events Following Immunisation (AEFIs)


BusinessToday.In
December 30, 2020
The expert committee on COVID-19 analysed the additional data and information that it had asked from SII and Bharat Biotech earlier this month


BusinessToday.In
December 30, 2020
This development comes hours after the UK government accepted the recommendation from the Medicines and Healthcare Regulatory Agency (MHRA) to authorise Oxford University-AstraZeneca's Covid-19 vaccine, named Covishield, for emergency use


BusinessToday.In
December 30, 2020
Oxford-AstraZeneca vaccine approved: The world's largest vaccine maker by volume, Serum Institute has already manufactured 50 million doses of Oxford-AstraZeneca vaccine on at-risk funding; the vaccine is cheap and easy to produce


PTI
December 29, 2020
Bharat Biotech MD also said the company has approached regulatory authorities seeking approval for an emergency license to use the vaccine, developed in collaboration with ICMR and the National Institute of Virology and now undergoing phase 3 trials


BusinessToday.In
December 29, 2020
Serum Institute of India (SII) CEO Adar Poonawalla said on December 28, that the vaccine is likely to get an emergency-use licence from the UK Medicines and Healthcare products Regulatory Agency as well as the Indian regulator, Drugs Controller General of India (DCGI), by early January


BusinessToday.In
December 29, 2020
Poonawalla says Covishield shows efficacy level of 95 per cent provided two shots are taken after a gap of 2-3 months; AstraZeneca will make that public with documentation soon, he adds


BusinessToday.In
December 29, 2020
The chief executive of Serum Institute - the biggest vaccine maker in the world by volume - said all trial data for Covishield has been provided to authorities in the UK and India as \"nobody wants to risk safety\"


PTI
December 27, 2020
The Oxford vaccine, which also has a tie-up with the Serum Institute of India, is expected to win approval in the UK before Thursday, speeding up the provision of the jab to the most vulnerable groups


PTI
December 27, 2020
Serum Institute of India (SII) has made a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine. The SII has already manufactured 40 million doses of the vaccine


BusinessToday.In
December 26, 2020
Pune-based SII is to submit an updated safety data of phase 2 and 3 clinical trials in India, immunogenicity data from the clinical trial in the UK and India, as well as the assessment results of the UK Medicines and Healthcare products Regulatory Agency


BusinessToday.In
December 25, 2020
COVAXIN also stated that promising results in the phase 1 and phase 2 trials of the Bharat Biotech COVID-19 vaccine have led to the phase 3 trials


BusinessToday.In
December 25, 2020
The SII CEO says considering the high demand for vaccines in the wake of coronavirus, the next decade could be a \"golden one\" for the entire vaccine industry


PAGES 6 OF 22  678910